港股異動丨光啟科學(0439.HK)大漲逾12% 售光啟技術股份 料錄收益近4,700萬人幣
格隆匯2月9日丨光啟科學(0439.HK)高開高走,現漲幅擴大至逾12%,報0.65港元,總市值40億港元。光啟科學今早公佈,集團已於今年1月20日至2月8日期間透過一系列交易在公開市場出售合共1,524.59萬股深圳證券交易所上市之光啟技術(002625.SZ)股份,總代價約為3.86億元人民幣(下同)。出售光啟技術股份之平均售價約為25.33元。於光啟技術出售事項後,估計銷售所得款項約為3.86億元,集團目前預期於今年之其他全面收益中就光啟技術出售事項確認約4,698萬元之公允值收益。

Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.